
Keywords: لیزین; mAb; charge heterogeneity; C-terminal Lys deletion; Lys and Gly deletion; pharmacokinetics; bioavailability; ATA; anti-therapeutic antibody; CDC; complement-dependent cytotoxicity; CL; clearance; ELISA; enzyme-linked immunosorbent assay; Fab; fragment ant